Clinical trials: Essential Hypertension
- Condition Essential Hypertension
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Hypertension
Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age
This double-blind 8 week study will evaluate dose response, efficacy (blood pressure lowering effect) and safety of aliskiren in children 6 - 17 years old with hypertension at low, mid and high weight-based doses.
- Trial name
- NCT01150357
- Testing
- Aliskiren (6.25/12.5/25 mg), Aliskiren (37.5/75/150 mg), Aliskiren (150/300/600 mg)
- Where
- 48 sites in United States, Belgium and 7 more
- Volunteers
- 267 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure
To assess the long-term (6 month and 12 month) safety of the combination of aliskiren 300 mg / amlodipine 10 mg in patients with essential hypertension (Mean Sitting Diastolic Blood Pressure [msDBP] ≥ 90 mmHg and < 110 mmHg).
- Trial name
- NCT00402103
- Testing
- Aliskiren, Amlodipine, Hydrochlorothiazide
- Where
- 8 sites in United States, Belgium and 6 more
- Volunteers
- 556 people
- Sponsor
- Novartis
Essential Hypertension
Effectiveness and Patient Self-assessed Compliance of Blood Pressure Treatment With Tarka® Fixed Combination in Patients With Essential Hypertension
The fixed combination of verapamil SR/trandolapril (Tarka®) is an effective, well-tolerated therapy for the treatment of essential hypertension in those who require more than one agent to achieve optimal blood pressure (BP)…
- Trial name
- NCT01127139
- Where
- 134 sites in Czechia
- Volunteers
- 3,828 people
- Sponsor
- Abbott
Hypertension
BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)
To evaluate the blood pressure efficacy between losartan and valsartan at equivalent dosage during a 3 months treatment.
- Trial name
- EASE (NCT00546754)
- Testing
- losartan potassium (+) hydrochlorothiazide, Comparator: Valsartan (+) Hydrochlorothiazide
- Volunteers
- 808 people
- Sponsor
- Organon and Co
Essential Hypertension
FimasaRtan-basEd BP Targets After Drug SwitcHing
The recent hypertension clinical practice guidelines published by American College of Cardiology (ACC) and American Heart Association (AHA) reduced the target BP to 130/80 mmHg, indicating the needs for more aggressive efforts in…
- Trial name
- FRESH (NCT03649646)
- Where
- South Korea
- Volunteers
- 4,542 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension
The purpose of this study is to compare the efficacy and safety of TAK-491 (azilsartan medoxomil), once daily (QD), to valsartan in participants with essential hypertension.
- Trial name
- NCT00591578
- Testing
- Azilsartan Medoxomil, Valsartan
- Where
- 88 sites in United States, Chile and 2 more
- Volunteers
- 984 people
- Sponsor
- Takeda
Hypertension
Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study
This study will evaluate the efficacy and safety of aliskiren 75 mg, 150 mg, and 300 mg in elderly patients with essential hypertension when given with a light meal.
- Trial name
- NCT00706134
- Testing
- Aliskiren 75 mg, Aliskiren 150 mg, Aliskiren 300 mg
- Where
- 8 sites in Argentina, Czechia and 6 more
- Volunteers
- 756 people
- Sponsor
- Novartis
Hypertension
Efficacy and Safety Study of Azilsartan Medoxomil Compared to Ramipril for Treating Essential Hypertension
The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil, once daily (QD), compared to ramipril for treating Essential Hypertension.
- Trial name
- NCT00760214
- Testing
- Azilsartan medoxomil, Ramipril
- Where
- 72 sites in Bulgaria, Estonia and 8 more
- Volunteers
- 885 people
- Sponsor
- Takeda
Essential Hypertension
Efficacy and Safety of Valsartan/Amlodipine Compared to Amlodipine in Patients With Essential Hypertension
This study was designed to compare the efficacy, tolerability, and safety of the combination valsartan/amlodipine 160/5 mg versus amlodipine 10 mg in patients with essential hypertension not adequately controlled (defined as mean…
- Trial name
- NCT00437645
- Testing
- Valsartan 160 mg capsules, Amlodipine 5 mg capsules
- Where
- 12 sites in Argentina, Chile and 10 more
- Volunteers
- 1,183 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with amlodipine in treating individuals with essential hypertension, compared to treatment with amlodipine…
- Trial name
- NCT00591266
- Testing
- Azilsartan Medoxomil and amlodipine, Amlodipine
- Where
- 50 sites in United States
- Volunteers
- 566 people
- Sponsor
- Takeda
Hypertension
Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension
This study will compare the efficacy and safety of once daily dosing of aliskiren monotherapy to once daily dosing of aliskiren and hydrochlorothiazide combination therapy in patients with Stage II hypertension over a period of…
- Trial name
- ACQUIRE (NCT00705575)
- Testing
- Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg), Aliskiren (300 mg)
- Where
- 8 sites in United States, Argentina and 6 more
- Volunteers
- 688 people
- Sponsor
- Novartis
Hypertension With Metabolic Syndrome
Efficacy and Safety of Aliskiren/Ramipril/Amlodipine Compared With Ramipril/Amlodipine and Aliskiren/Amlodipine in Patients With Metabolic Syndrome
This proof of concept study is designed to evaluate the efficacy and safety of the combination therapy of aliskiren and ramipril as add-on to amlodipine in the treatment of patients with essential hypertension and metabolic…
- Trial name
- ALTO (NCT00542269)
- Testing
- Amlodipine, Aliskiren, Ramipril
- Where
- United Kingdom
- Volunteers
- 178 people
- Sponsor
- Novartis
Essential Hypertension
Helius in Hypertension-I: The UK Hypertension Registry
The purpose of this study is to demonstrate the use of a digital health offering in the management of persistent hypertension during chronic anti-hypertensive treatment.
- Trial name
- NCT02553512
- Testing
- Ingestible Sensor and Wearable Sensor
- Volunteers
- 151 people
- Sponsor
- Proteus Digital Health, Inc.
Essential Hypertension
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension
This study tested the safety of the combination of aliskiren/amlodipine/hydrochlorothiazide in participants with essential hypertension.
- Trial name
- NCT00667719
- Testing
- Aliskiren, Amlodipine, Hydrochlorothiazide
- Where
- 8 sites in United States, Belgium and 6 more
- Volunteers
- 564 people
- Sponsor
- Novartis
Hypertension
MK-0954E Phase III Long-Term Study in Participants With Hypertension (MK-0954E-356)
This study has two parts. In the first part, the efficacy and safety MK-0954E (losartan potassium 50 mg [L50] (+) hydrochlorothiazide 12.5 mg [H12.5] (+) amlodipine besylate 5mg [A5]) will be evaluated and compared to the…
- Trial name
- NCT01299376
- Testing
- L50/H12.5/A5, L50/H12.5
- Volunteers
- 286 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
This study was a dose-ranging efficiacy study in patients with essential hypertension to assess the blood pressure lowering effect, and safety of LCZ696 compared to valsartan and placebo.
- Trial name
- NCT00549770
- Testing
- LCZ696, Valsartan, AHU377
- Where
- 182 sites in United States, Argentina and 16 more
- Volunteers
- 1,334 people
- Sponsor
- Novartis Pharmaceuticals
Essential Hypertension ( Mild to Moderate)
Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension
This study will assess the efficacy of an aliskiren based treatment regimen in reaching blood pressure (BP) target in patients with mild to moderate hypertension.
- Trial name
- NCT00765947
- Testing
- Aliskiren, Hydrochlorothiazide, Amlodipine
- Where
- 4 sites in France, Hungary and 2 more
- Volunteers
- 256 people
- Sponsor
- Novartis
Hypertension, Stroke
A Blood Pressure Regulation and Stroke Risk Evaluation Study in Hypertensive Patients Treated With Eprosartan
The primary objective of the study is to evaluate the proportion of hypertensive patients who achieve regulation of their blood pressure (BP) levels according to the European Society of Cardiology / European School of Haematology…
- Trial name
- NCT01562613
- Where
- 84 sites in Greece
- Volunteers
- 533 people
- Sponsor
- Abbott
Hypertension
An Extension Study to Evaluate the Long Term Safety, Tolerability and Efficacy of Aliskiren Compared to Enalapril in Pediatric Hypertensive Patients 6-17 Years of Age
The purpose of this study is to evaluate in a randomized, double-blind fashion, the long-term safety, tolerability and efficacy profile of aliskiren compared to the active comparator enalapril in children, 6 - 17 years old with…
- Trial name
- NCT01151410
- Testing
- Aliskiren, Enalapril
- Where
- 36 sites in United States, Guatemala and 5 more
- Volunteers
- 208 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension
This study will evaluate the long-term gastrointestinal (GI) safety and efficacy of aliskiren (300 mg) compared to ramipril (10mg) in patients ≥ 50 years with essential hypertension.
- Trial name
- NCT00631917
- Testing
- Aliskiren, Ramipril
- Where
- 7 sites in United States, Argentina and 5 more
- Volunteers
- 774 people
- Sponsor
- Novartis